Presto JK, et al. - An inquiry was set up with regard to the R333 (topical janus kinase and spleen tyrosine kinase inhibitor) efficacy in the treatment of discoid lupus erythematosus (DLE). Furthermore, experts intended to analyze the area of active DLE lesions. No notable improvement was achieved in the lesion activity following 4 weeks of R333 therapy. When compared to the area change using two-dimensional measurements, lesion activity and area change using computerized planimetry served as better determinants of responsiveness.